120 related articles for article (PubMed ID: 34243080)
21. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
22. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
23. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
24. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
25. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
Katz MH; Varadhachary GR; Fleming JB; Wolff RA; Lee JE; Pisters PW; Vauthey JN; Abdalla EK; Sun CC; Wang H; Crane CH; Lee JH; Tamm EP; Abbruzzese JL; Evans DB
Ann Surg Oncol; 2010 Jul; 17(7):1794-801. PubMed ID: 20162463
[TBL] [Abstract][Full Text] [Related]
26. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
27. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
29. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis.
Raza SS; Khan H; Hajibandeh S; Hajibandeh S; Bartlett D; Chatzizacharias N; Roberts K; Marudanayagam R; Sutcliffe RP
HPB (Oxford); 2024 May; 26(5):630-638. PubMed ID: 38383207
[TBL] [Abstract][Full Text] [Related]
30. Selection criteria in resectable pancreatic cancer: a biological and morphological approach.
Tamburrino D; Partelli S; Crippa S; Manzoni A; Maurizi A; Falconi M
World J Gastroenterol; 2014 Aug; 20(32):11210-5. PubMed ID: 25170205
[TBL] [Abstract][Full Text] [Related]
31. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
32. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
33. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
35. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.
Liu L; Xu HX; Wang WQ; Wu CT; Xiang JF; Liu C; Long J; Xu J; Fu de L; Ni QX; Houchen CW; Postier RG; Li M; Yu XJ
Oncotarget; 2016 Feb; 7(5):5943-56. PubMed ID: 26745601
[TBL] [Abstract][Full Text] [Related]
36. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
38. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
39. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
40. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
Månsson C; Nilsson A; Urdzik J; Karlson BM
Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]